Article
Two different patterns of lung adenocarcinoma with concomitant EGFR mutation and ALK rearrangement.
Tumori - 1 Feb 2022
Zhao Dashi, Fan Jun, Peng Li, Huang Bo, Zhu Yili, Shi Heshui, Dai Xiaofang, Nie Xiu
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are considered mutually exclusive in non-small cell lung cancer (NSCLC), especially in lung adenocarcinoma (LUAC). However, sporadic cases harboring concomitant EGFR and ALK alterations have been increasingly reported. There is no consensus opinion regarding the treatment of patients positive for both molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
